Kezar ends lupus trial after fatal SAEs, adopts poison pill to block $1.10 bid

Kezar Life Sciences, Inc.

Discontinued PALIZADE Phase 2b in lupus nephritis after 4 Grade 5 SAEs (1 placebo); 84 patients enrolled.
PORTOLA Phase 2a in autoimmune hepatitis continues; topline data due H1 2025.
Board rejected Concentra's $1.10/share bid; adopted rights plan (10%/15% threshold, expires Oct 17, 2025).
Preliminary cash ~$148M as of Sep 30, 2024; company says cash runway extended.
Concentra accumulated 9.9% of KZR; grandfathered but cannot increase without triggering rights.

item 1.01 item 2.02 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.7

Kezar Life Sciences, Inc.: Board approved Certificate of Designations establishing Preferred Shares; filed with Delaware Secretary of State on October 17, 2024 (effective 2024-10-17).

Change: charter amendment
Effective: 2024-10-17

Exact text from the filing

the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 17, 2024.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-238562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.